Brexu-cel Clinical Practice Safety Report by Lymphoma CAR T Consortium

Hackensack University Medical Center Among Centers Reporting Positive Results at American Society of Hematology Meeting

Andre Goy MD

At the 2021 American Society of Hematology meeting, the U.S. Lymphoma CAR T Consortium reported positive safety and efficacy evaluation of brexu-cel in standard of care practice for relapsed/refractory (R/R) mantle cell lymphoma (MCL) among 14 of its participant centers.

Brexucabtagene autoleucel (brexu-cel) was FDA approved for R/R MCL mid-2020 based on results of the ZUMA-2 study, which recorded an objective response rate of 93% and a complete response rate of 67%. The study maintained stringent eligibility criteria, including prior treatment with a BTK inhibitor (BTKi), and only allowed BTKi and/or corticosteroid for bridging therapy.

As follow-up, fourteen consortium centers participated in this retrospective study to examine whether these results are replicable in a real-world clinical setting. The evaluation demonstrated encouraging safety and efficacy data of brexu-cel in R/R MCL in clinical practice. The CRS and ICANS incidences were comparable to those reported in ZUMA-2, though the use of tocilizumab and steroid was more frequent than in ZUMA-2. Although 73% of the patients would have been ineligible for ZUMA-2, the ORR and CR rate were comparable to those reported in ZUMA-2.

While extended follow-up is necessary to confirm long-term safety and efficacy, these initial results offer promising real-world validation of the ZUMA-2 study findings.

Learn more about cancer care breakthroughs at Hackensack University Medical Center.

US News Badge
We use cookies to improve your site experience. By using this site,
you agree to our Terms & Conditions. Also, please read our Privacy Policy.
Accept All Cookies